Literature DB >> 2567801

Survival and causes of death in thalassaemia major.

M G Zurlo1, P De Stefano, C Borgna-Pignatti, A Di Palma, A Piga, C Melevendi, F Di Gregorio, M G Burattini, S Terzoli.   

Abstract

Survival and causes of death were studied in 1087 Italian patients with thalassaemia major who were born on or after Jan 1, 1960. At the age of 15 years, the Kaplan-Meier estimate of survival after the first decade of life was 80.6% for subjects born in 1960-64, 84.2% for those born in 1965-69, and 96.9% for those born in 1970-74. At the age of 20 years, survival from the age of 10 was 59.1% for patients born in 1960-64, and 70.2% for those born in 1965-69; at 25 years, survival from the age of 10 was 40.7% in the 1960-64 cohort. Overall survival from birth for patients born in 1970-74 was 97.4% at 10 years, and 94.4% at 15 years. The most common cause of death was heart disease, followed by infection, liver disease, and malignancy.

Entities:  

Mesh:

Year:  1989        PMID: 2567801     DOI: 10.1016/s0140-6736(89)90264-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  125 in total

1.  Pulmonary function tests in beta thalassemia.

Authors:  M Arora; J Chandra; J C Suri; S Narayan; A K Dutta
Journal:  Indian J Pediatr       Date:  2001-03       Impact factor: 1.967

2.  Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia.

Authors:  A Phrommintikul; A Sukonthasarn; R Kanjanavanit; W Nawarawong
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

Review 3.  Hypercoagulability in congenital haemolytic anaemias.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2012-10-25       Impact factor: 3.443

4.  The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Authors:  Raymond J Bergeron; Neelam Bharti; Jan Wiegand; James S McManis; Shailendra Singh; Khalil A Abboud
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

5.  Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.

Authors:  Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi-Kong Li; Vip Viprakasit; Mohsen Saleh Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

6.  Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

Authors:  Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi-Kong Li; Vip Viprakasit; Mohsen S Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

7.  Improved R2* measurements in myocardial iron overload.

Authors:  Nilesh R Ghugre; Cathleen M Enriquez; Thomas D Coates; Marvin D Nelson; John C Wood
Journal:  J Magn Reson Imaging       Date:  2006-01       Impact factor: 4.813

8.  The design, synthesis, and evaluation of organ-specific iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2006-11-30       Impact factor: 7.446

9.  Life expectancy and risk factors for early death in patients with severe thalassemia syndromes in South India.

Authors:  Rakesh Dhanya; Amit Sedai; Kumari Ankita; Lalith Parmar; Rajat Kumar Agarwal; Santhosh Hegde; Gayathri Ramaswami; Ashwini Gowda; S Girija; Pooja Gujjal; H Pushpa; J Dasaratha Ramaiah; Chandrakala Karri; Sujata Jali; Neelavva Rayappa Tallur; U V Shenoy; Diana Pinto; Stalin Ramprakash; C P Raghuram; Deepa Trivedi; Xueyuan Cao; Lawrence Faulkner
Journal:  Blood Adv       Date:  2020-04-14

10.  Cardiac iron overload in thalassemic patients: an endomyocardial biopsy study.

Authors:  T Lombardo; C Tamburino; G Bartoloni; M L Morrone; V Frontini; F Italia; S Cordaro; A Privitera; V Calvi
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.